Enhancing Value of Information Analyses  by Janssen, Mart P. & Koffijberg, Hendrik
EnhancingValue of Information Analysesvhe_548 935..941
Mart P. Janssen, MSc, Hendrik Kofﬁjberg, PhD
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht,The Netherlands
ABSTRACT
Objective: The aim of this study was to demonstrate that it is
feasible and recommendable to present value of information (VOI)
outcomes in terms of underlying costs and effects in addition to costs
alone.
Methods: The beneﬁts of collecting additional information on health eco-
nomic outcomes before deciding on a preferred policy when evaluating
alternative strategies with uncertain outcomes are quantiﬁed in a VOI
analysis. In general, costs and effects are combined into one single dimen-
sion to determine the expected monetary VOI. Separate information on
costs and effects is lost. This information, however, remains relevant to the
decision-maker. The concept of the attributable VOI (AVOI) is introduced
which enables separate presentation of expected changes in health out-
comes and costs.
Results: The use of the attributable expected value of perfect information
is illustrated with a few examples. These examples demonstrate the ben-
eﬁts of the new approach, as well as its calculation. The beneﬁts are: 1)
insight into the expected costs and expected effects gained as a result of
carrying out further research to reduce or eliminate decision uncertainty;
and 2) the likelihood that the outcome of additional research will result in
a change in preferred policy.
Conclusions: Decision-making may be enhanced and clariﬁed by adding
results from AVOI analyses. Obtaining these results is straightforward and
requires only a minimal computational effort. Therefore, use of the AVOI
extension is recommended for all future VOI analyses.
Keywords: attributable value of information, decision uncertainty, eco-
nomic evaluation, simulation.
Introduction
With the continuous rise of health-care costs, efﬁciency of health
care and health-care research is becoming increasingly impor-
tant. Value of information (VOI) analyses allows a systematic
quantiﬁcation of the expected ﬁnancial gain from additional
information for decisions made under uncertainty. These kind of
analyses are increasingly applied in health policy research and
health technology assessment [1–5]. VOI outcome is proposed as
a measure for setting priorities on additional research among
research projects, as it indicates a project’s potential for return on
investment. Nevertheless, there is a price to be paid for obtaining
the VOI. In a conventional comparison of health-care interven-
tions, outcomes are projected in a cost-effectiveness plane, giving
information on incremental costs and effects for all interventions.
Calculating the VOI is done within a net monetary beneﬁt
(NMB) framework. Within this framework, the setting of a par-
ticular cost-effectiveness threshold (CET) is deﬁned which pro-
vides a means for valuating health effects in terms of their
monetary equivalent. This enables a decision on the preferred
intervention for any combination of intervention outcomes. This
is the one with the highest monetary equivalent (i.e., the highest
NMB). Nevertheless, as costs and effects are combined into one
single dimension, information on each of the separate dimensions
is lost. This information, however, can be—and we will argue
that it is—relevant to the decision-maker.
We develop the concept of “attributable VOI” (AVOI). The
AVOI is a straightforward extension of the general VOI concept
whereby it is split into separate parts for costs and effects that
add up to the total VOI. We will demonstrate and apply this
concept to the measure of expected value of perfect information
(EVPI). The AVOI allows the decision-maker to judge not only
the value of additional research, but also its impact in terms of
the expected shift in costs and effects as compared to the cur-
rently preferred intervention. These additional insights improve a
decision-maker’s ability to evaluate the merits of additional
research.
Methods
Standard EVPI
Measures such as the EVPI and the expected value of sample
information (EVSI) may be used for research prioritization,
based on comparisons between expected beneﬁts and costs of
future research projects [6]. The EVPI was introduced in the
1960s and has a straightforward interpretation: It is the differ-
ence between the expected utility of the decision when no uncer-
tainty exists (perfect information) and expected utility of the
decision based upon current evidence [7]. In a health economic
context, effects are usually expressed in terms of quality-adjusted
life-years (QALYs). Subsequently, the NMB is used to determine
the utility of a particular outcome of an intervention [8]. The
NMB (Equation 1) is a simple linear function of the CET, costs
(C in $), and effects (Q in QALYs). The preferred intervention is
the one with the highest expected NMB. The EVPI as function of
the CET over all interventions j with respect to the parameter
space W of costs and effects (with realizations w) is given by
Equation 2.
NMB CET CETj Q j C j, , , ,ω ω ω( ) = ⋅ ( ) − ( ) (1)
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For each intervention, the bivariate (correlated) distribution of
intervention outcomes (costs and effects) is required for the cal-
culation of the EVPI. The second part of Equation 2 refers to the
mean NMB for each of the interventions considered. Conversely,
the ﬁrst part of this equation refers to the mean (of the
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maximum) NMB for each potential combination of outcomes
separately. This mimics the situation where the best decision is
taken in each viable situation.
Despite the simple form of Equation 2, it does not reveal any
characteristics of the EVPI. For example, it does not reveal how
the EVPI is affected by differences in costs and effects between
interventions and their dispersion. This complicates the under-
standing of the EVPI at the basic level: EVPI values cannot be
interpreted in terms of costs and effects.
EVPI and the Segregation of Costs and Effects
The transformation of intervention outcomes to an NMB is
required to decide on the preferred intervention, which is the one
with the highest expected NMB. In the calculation of the EVPI,
the outcome of either intervention is expressed in the NMB
which results in a monetary equivalent in which the EVPI is
expressed. Nevertheless, as the NMB in Equation 2 for any given
j and w is calculated using Equation 1 with speciﬁc cost-and-
effect outcomes, the contribution of costs and effects to the EVPI
can be separated. This only requires taking the respective costs or
effects associated with the intervention that maximizes the NMB
of Equation 2. By doing this, the attributable costs (Equation 3a)
and attributable effects (Equation 3b) of the EVPI are obtained.
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The functions fc and fe in Equation 3 refer to the respective
underlying costs and effects associated with the NMB they are
applied to. The fact that the NMB is a linear combination of
costs and effects implies that the functions fc and fe can also be
applied to the expected value of the NMB. The results are equiva-
lent to the expected costs and expected effects, respectively. Also,
the attributable effects multiplied by the CET minus the attrib-
utable costs are equivalent to the EVPI.
Simulations to Illustrate the Additional Value of the
Attributable EVPI (AEVPI)
To illustrate how the AEVPI can support decision-making, three
examples are given. For each example, the standard EVPI and
AEVPI are calculated. In addition, a step-by-step illustration of
how the AEVPI is calculated will be provided for one of the
examples. Calculations were performed using Microsoft Excel®
(MS-Excel 2002, Microsoft Corp., Redmond, WA) and R®
(version 2.7.2, The R Foundation for Statistical Computing,
Vienna, Austria). A fully accessible spreadsheet and R code con-
taining the examples presented in this article can be obtained
from the authors upon request.
Results
Calculation of the EVPI requires a probabilistic estimation of
costs and effects of two interventions and a CET. For both
interventions, the distributions of costs and effects are generally
presented graphically in a cost-effectiveness plane. Figure 1
shows an example of a cost-effectiveness plane with a generic
decision problem concerning two interventions: intervention (1)
with expected outcome P1, and intervention (2) with expected
outcome P2. The uncertainty in the outcomes of P1 and P2 is
visualized as a 95% conﬁdence interval for their respective costs
and effects. In this example, costs and effects follow uncorrelated
normal distributions. Mean costs and effects, as well as the
dispersion of these outcomes, are known: for intervention (1), the
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Figure 1 Attributable expected value of perfect
information (EVPI) of example 1. Shown are the
mean costs, effects, and 95% conﬁdence contours
of two interventions (P1 and P2), their respective
expected mean costs, and effects conditional on
being the preferred intervention while knowing
their exact outcomes (P1* and P2*), and the
expected outcome conditional on perfect informa-
tion (A). The attributable EVPI is represented by
the difference between A and P1, and consists of
attributable costs and attributable effects. Interven-
tion (1) (P1) is normally distributed with costs
$1000 (SD $600) and effects 0.2 quality-adjusted
life-years (QALYs) (SD 0.3 QALYs). Intervention
(2) (P2) is normally distributed with costs $400 (SD
$1000) and effects 0.1 QALYs (SD 0.2 QALYs).
The EVPI for this decision problem is $2755; the
AEVPICost and AEVPIEffect are -$309 and 0.098
QALYs, respectively.
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mean costs are $1000 with an SD of $600. The mean effect is
0.2 QALYs (SD 0.3 QALYs); intervention (2) has mean costs
of $400 (SD $1000) and mean effect of 0.1 QALYs (SD
0.2 QALYs). In Figure 1, a line is drawn through P1 which rep-
resents a CET of $25,000 per QALY. Any point on this line
has an NMB that is equal to that of intervention (1). Given
this CET, intervention (1) is the preferred intervention because P2
lies above the CET line, which implies that P2 has the lesser
expected NMB. The expected NMB of intervention (1) equals
0.2 QALYs ¥ $25,000 per QALY - $1000 = $4000. The
expected NMB of intervention (2) equals 0.1 QALYs ¥ $25,000
per QALY - $400 = $2100. Nevertheless, although the expected
NMB of intervention (1) exceeds the expected NMB of interven-
tion (2), there is a chance, given the uncertainty in costs and
effects of both interventions, that the NMB of intervention (2) is
the highest. In that case, intervention (2) is to be preferred. Points
P1* and P2* represent the expected costs and expected effects of
those outcomes that have either intervention (1) or (2), respec-
tively, as the preferred intervention. Point A indicates the mean
costs and effects of the preferred intervention (irrespective of this
being (1) or (2)). Point A is the average of P1* and P2*, weighting
each of these with their respective probability of being the pre-
ferred intervention. The cost difference between P1 and A repre-
sents the AEVPI cost, whereas the effect difference between P1
and A represents the AEVPI effect. This is the graphical equiva-
lent of Equation 3.
Example Calculations
The calculation of the AEVPI is illustrated using the example
given in Figure 1. The results are shown in Table 1. This table
shows simulated costs and effects for both interventions. Samples
were drawn randomly from aforementioned normal distribu-
tions. From Table 1, it can be found that the estimated average
NMB on the basis of 20 samples is $4371 and $1025 for inter-
ventions (1) and (2), respectively (“Sample average” row of
columns C and F). Intervention (1) would be (correctly) consid-
ered the preferred intervention on the basis of this limited
sample. The AEVPI cost (AEVPICost) is estimated at -$314 and
the AEVPI effect (AEVPIEffect) at 0.084 QALYs. The attributable
effect value (i.e., the cost equivalent of the attributable effect
(AEVPIEffect Value), is found by multiplying the attributable effect
with the CET (0.084 ¥ 25,000 = $2100). Note that the attribut-
able effect value minus the attributable costs is indeed—apart
from rounding errors—equal to the EVPI ($2410).
It is common to represent the value of the EVPI graphically as
a function of the CET. In Figure 2, this relation is shown for the
EVPI and, in addition, for the attributable cost and attributable
effect values. Please note that minus the AEVPICost is shown so
that the sum of the AEVPI lines equals the (total) EVPI. From
Figure 2 is apparent that for a CET less than $6000 per QALY,
both the AEVPIEffect Value and AEVPICost are increasing. As the
-AEVPICost line is declining, the AEVPICost is increasing. Here,
intervention (2) is the preferred intervention. At $6000 per
QALY, the decision-maker is indifferent as the expected NMB is
equal for both interventions. For larger CET values, intervention
(1) is preferred. At a CET of zero, intervention (1) will only
be preferred in case it results in lower costs. Therefore, the
AEVPICost at this point is negative, and minus the AEVPICost in
Figure 2 is positive. As long as there is uncertainty with respect to
the sign of the relative effect outcome, the contribution of the
AEVPIEffect Value to the EVPI will increase with an increasing CET.
This is the cause for the unlimited growth found in many EVPI
curves. For a CET of $6000 per QALY, the preferred intervention
changes. As a result, the AEVPIs show a discontinuity as the
outcome reference point (second term in Equations 2 and 3) is no
longer the expected outcome of intervention (2), but that of
intervention (1). For higher CETs, the EVPI is dominated by the
effect outcome, and the AEVPICost becomes dependent on the
probability that intervention (2) is more effective than interven-
tion (1). As in this setting, this probability becomes rather insen-
sitive to changes in CET values over $6000 per QALY, the
AEVPICost only slowly increases beyond this point.
Additional Examples
Two more examples of a decision between two interventions with
uncertain outcomes are given in Figures 3 and 4. A summary of
the characteristics and the outcomes of all examples is given in
Table 2. In Figure 3 (example 2), a situation is given where
intervention (2) is shifted upward along the CET line such that
the expected effect is doubled. Comparing NMB outcomes
between interventions (1) and (2) in this example will therefore
give the same results as when comparing NMB outcomes in
Example 1. Hence, the EVPI of example 1 is identical to that of
example 2, and cannot be used to distinguish between them.
The difference between these two situations, however, is
clearly illustrated by the AEVPI. In example 1, the AEVPI costs are
-$309 whereas in example 2 these are $734. From the presenta-
tion in the cost-effectiveness plane, it is clear that the outcome of
additional research is likely to result in a preferred strategy which
has higher expected costs and effects. EVPI is sometimes presented
without information on relative cost-effectiveness of interven-
tions, especially when multiple interventions are compared [9].
On the other hand, when taking decisions on strategic research
investments to improve decision-making, apart from the expected
value of the investment (the EVPI), the impact of the research
outcomeswill be ofmajor concern to the decision-maker: he or she
would like to knowwhether the outcome of additional research is
going to increase or decrease health-care costs and effects, what
the likelihood of such scenarios is, and what the likelihood is that
the outcome of additional research is going to change current
policy. The ﬁrst question is answered exactly by the AEVPI as it
represents the expected change in costs and effects of additional
research relative to the currently preferred intervention. The
second question can be answered by looking at the “direction of
change” probabilities for each of the quadrants: in example 1,
there is 31% probability (Q3 + Q4 = 4% + 27%; Table 2) that
obtaining perfect information will result in a cost reduction,
whereas in example 2 there is a 39% (Q1) probability that this will
result in an increase in costs (Table 2). The third question ismerely
the sum of the probabilities of change for the three relevant
quadrant directions (Q1, Q3, and Q4).
In example 3 (Fig. 4), intervention (1) is compared to an
expensive intervention with a highly uncertain effect. Interven-
tion (2) has expected costs of $5000 (SD $500) and expected
effects of -6 QALYs (SD 5 QALYs). As a result of the high
uncertainty of the effect outcome, intervention (2) can potentially
be far more effective than intervention (1). The beneﬁts of reduc-
ing the current decision uncertainty are expressed in an EVPI of
$6078. This is more than twice the EVPI from example 1. Nev-
ertheless, although the VOI for this situation is considerably
higher, adopting intervention (2) results in an increase in treat-
ment costs. This is expressed in the AEVPICost, which in this case
equals +$408 compared with -$309 in example 1. Moreover,
there is a high chance (90%) that the additional research will not
change the current preferred policy at all. This poses a higher
(political) investment risk. Note that at the same time the returns
can also be substantially higher, which is reﬂected in the higher
EVPI. Nevertheless, the EVPI estimates presume a neutral risk
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Figure 2 Expected value of perfect information
(EVPI) and attributable EVPIs (AEVPIs) of example
1. Please note that minus theAEVPICost is shown so
that the sum of the AEVPI lines equals the (total)
EVPI.
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Figure 3 Attributable expected value of perfect
information (AEVPI) example 2.Average outcome
and 95% conﬁdence contours of intervention (1)
(P1) with normally distributed costs $1000 (SD
$600) and effects 0.2 quality-adjusted life-years
(QALYs) (SD 0.3 QALYs), and intervention (2) (P2)
with normally distributed costs $2900 (SD $1000)
and effects 0.2 QALYs (SD 0.2 QALYs). The EVPI
for this decision problem is $2755; the AEVPICost
and AEVPIEffect are $734 and 0.140 QALYs,
respectively.
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attitude which might not at all be the risk attitude of the decision-
maker. Both the impact on treatment costs and probability of
policy change are important factors a decision-maker would like
to take into consideration when comparing VOI outcomes.
Discussion
There are various other types of VOI analyses available in addi-
tion to the EVPI analysis as described in this article [6,10]. An
example is the “expected value of partial perfect information”
(EVPPI) [11]. Here, not the beneﬁt from eliminating uncertainty
in all model parameters is obtained, but of that of a particular
parameter or a set of parameters. Another measure is the analysis
of the EVSI [12]. In an EVSI analysis, a more realistic scenario for
obtaining additional information (e.g., by performing a clinical
trial) is deﬁned and gains on improved decision-making are
quantiﬁed. The outcomes of all current VOI analyses are ham-
pered by the same limitations as described in this article. Fortu-
nately, as the concept of calculating AVOI applies to the way
results are presented and not to the way they are obtained, it can
be applied to any VOI analysis. Often, VOI results are presented
as a function of the CET (in case of EVPI of EVPPI), or as a
function of the size of an additional randomized trial (in case of
EVSI). This allows the decision-maker to analyze the sensitivity
of the VOI. Any of these standard VOI results can easily be
extended with AVOI results. As an example, Figure 2 provides
attributable cost and effect values as a function of the CET.
VOI analyses are generally performed by Monte Carlo simu-
lations. Estimating the AVOI is as straightforward (or challeng-
ing) as estimating any of the existing VOI measures.
Nevertheless, as both costs and effects are required for calcula-
tion of the NMB, which in turn is required to determine the
preferred intervention, it is merely a matter of collecting the
correct samples to enable calculation of the AVOI. This can be
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Figure 4 Attributable expected value of perfect
information (AEVPI) example 3.Average outcome
and 95% conﬁdence contours of intervention (1)
(P1) with normally distributed costs and effects of
$1000 (SD $600) and 0.2 quality-adjusted life-years
(QALYs) (SD 0.3 QALYs) and intervention (2) (P2)
with normally distributed costs $5000 (SD $500)
and effects -6 QALYs (SD 5 QALYs). The EVPI for
this decision problem is $6079; the AEVPICost and
AEVPIEffect are $408 and 0.259 QALYs, respectively.
Table 2 Summary of characteristics and outcomes of all examples
Description
Outcome of Intervention (2)*
Average (SD) AEVPICost AEVPIEffect AEVPIEffect Value† EVPI
Direction of change
probabilities‡
Probability of change of
preferred intervention
Cost ($) Effect (QALY) ($) (QALY) ($) ($)
(Q2) (Q1)
(Q3) (Q4)
Q1 +Q2
+Q3 +Q4
Example 1 400 (1000) 0.1 (0.2) -309 0.098 2446 2755 Q2 = 0%, Q1 = 11% 42%
(Fig. 1) Q3 = 4%, Q4 = 27%
Example 2 2900 (1000) 0.2 (0.2) 734 0.140 3489 2755 Q2 = 0%, Q1 = 39% 42%
(Fig. 3) Q3 = 0%, Q4 = 3%
Example 3 5000 (500) -6.0 (5.0) 408 0.259 6486 6079 Q2 = 0%, Q1 = 10% 10%
(Fig. 4) Q3 = 0%, Q4 = 0%
*The average cost of intervention (1) is $1000 (SD $600), and the average effect is 0.2 QALYs (SD 0.3 QALYs).
†The AEVPIEffect Value is the product of the AEVPIEffect and the CET ($25,000 per QALY).
‡Direction of change probabilities indicate the probability that the alternative intervention will either increase costs (Q1 and Q2), decrease costs (Q3 and Q4), increase effects (Q1 and Q4),
or decrease effects (Q2 and Q3).
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done with virtually no computational overhead to any of the
existing procedures.
The AVOI provides a means to add relevant information to
the current VOI, by providing the decision-maker with insight
into the expected outcome of additional research in terms of
changes in costs and effects of future interventions. In addition,
the probability of change in any particular direction can be
provided (e.g., the likelihood that costs and effects will increase
[or decrease] as a result of the outcomes of additional research).
Also, it allows assessment of the likelihood that the additional
research will result in a change in current policy with respect to
the preferred intervention. This additional information can be
decisive when a selection has to be made between multiple
research projects. The advantages of the AVOI in combination
with the limited computational overhead required lead us to
strongly recommend AVOI as a general extension to the existing
presentation of VOI results.
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